本季度信息
绿新生物科技（股票代码：01084）发布公告显示，截至2025年12月31日，公司营收同比出现下滑，经调整净利润预计不超过0.08亿元人民币，而2024财年同期经调整净利润约为0.622亿元人民币。公告指出，净利润出现明显下跌主要源于公司主要亲水胶体产品价格与销量下降，导致收益及毛利减少。根据公司初步测算，管理层预计2025财年经调整净利润与去年同期相比降幅显著。
公司方面强调，相关数据尚未经过审计，最终结果可能存在调整。根据公告，完整的2025财年业绩将在2026年3月底前对外披露。
业务分项
公告提到，公司主要的亲水胶体产品对整体营收和净利润影响较大。由于该类产品价格及销量下降，直接导致营业收入与毛利水平下降，从而削弱了公司的整体盈利能力。公司目前仍在对经营数据进行进一步审慎评估，后续或将根据市场需求和产品结构作出调整以应对相关挑战。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.